About Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding
KWF is the Netherlands’ leading cancer charity and research funder, supporting the full continuum from prevention and early detection to treatment, implementation, and life after cancer. Its grantmaking is strongly science-driven and nationally focused, with a clear emphasis on turning oncology research into patient-relevant practice through clinical translation, implementation, and shared research infrastructure. It tends to fund Dutch universities, UMCs, cancer institutes, research consortia, and early-career investigators rather than broad community nonprofits.
Focus Areas
Cancer ResearchClinical Translation in OncologyImplementation Science in Cancer CareEarly-Career Cancer ResearchersHigh-Risk Exploratory Oncology ResearchCancer Research Infrastructure and Shared Platforms
Giving Approach
Competitive, program-based grantmaking with indicative budgets rather than open-ended awards. Grants are typically multi-year and can be substantial (often several hundred thousand euros), with separate calls for project research, implementation, young investigators, high-risk pilot work, consortia, and infrastructure; some programs are explicitly geared to national-scale adoption in the Netherlands.
Recent grants from Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding's latest annual report (2040)
Grants parsed from this funder's most recently published annual report.
Recipient
Amount
Year
Purpose
Belangrijke partners die we
• In 2040 is de Nederlan
2040
—
hoe bacteriën in je darmen h
• In 2032 drinken zwang
2040
—
stimuleren en andere het juis
• In 2032 worden mense
2040
—
deze manier willen we:
Institute in 2025 was een
2040
—
immuuntherapie bepalen. D
18 jaar geen alcohol, on
Want a Personalized Pitch for Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding?
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Monitor KWF’s program-specific calls and apply through the relevant research or implementation track; eligibility is generally limited to Dutch-based institutions and collaborations. Tailor proposals to patient-relevant outcomes, demonstrate added value for oncology practice, and for implementation or consortium grants show readiness for national uptake, strong collaboration, and clear budget justification.
Notable grantees:
• LUMC
• Amsterdam UMC
• Oncode Institute
• Antoni van Leeuwenhoek / Nederlands Kanker Instituut
Current and upcoming funding from Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding that your nonprofit may be able to apply for.
Open nowCloses Feb 23, 2027May not accept unsolicited proposalsAward: $1.2M – $4.6M
Implementation of Biomarkers 2027
Biomarker implementationClinical utilityNationwide adoption+2 more
Who can apply: Projects must involve a clinical-grade biomarker at TRL 7 or beyond and address clinical implementation, patient needs, patient involvement, HTA, implementation science and sustainable integration into routine care. A project manager and KWF-approved steering committee are required.
Deadline: The 2027 timeline was not specified in the scraped content.
Cancer researchEarly-career researcher developmentBasic research+2 more
Who can apply: Intended for researchers at an early stage of their scientific career. Proposals may cover Basic through Implementation research phases and must meet KWF eligibility requirements.
Deadline: Pre-proposals close 6 October 2026 at 12:00 noon; full proposals close 1 April 2027 at 12:00 noon.
Novel cancer drug developmentPreclinical developmentIND-enabling studies+2 more
Who can apply: Applicants must be researchers or private parties based in the Netherlands, with ownership or rights to the investigational medicinal product and freedom to operate. Projects must involve novel oncology drug candidates in late-stage preclinical development or approaching first-in-human studies. Non-Dutch initiators, repurposing projects and products with limited freedom to operate are excluded.
Deadline: Year-round; no specific submission deadlines.
Opening soonCloses Mar 16, 2027May not accept unsolicited proposalsAward: Varies
2027-Development Call
Creation of modalitiesPreclinical researchClinical research+2 more
Who can apply: Proposals must fall within the Creation of Modality, Preclinical, Clinical or Implementation research phases. Projects aligned with specified thematic calls are excluded. Public-private partnerships are encouraged.
Deadline: Full proposals close 16 March 2027 at 12:00 noon.
Opening soonCloses Aug 24, 2027May not accept unsolicited proposalsAward: No grant amount specified.
EQUATOR-2027: Towards Equal and Inclusive Cancer Care
Equitable cancer careInclusive cancer careLifestyle in cancer care+4 more
Who can apply: Projects should use multidisciplinary teams involving relevant national stakeholders, including researchers, healthcare professionals, policymakers and patient representatives.
Deadline: Pre-proposals open 19 January 2027 and close 6 April 2027 at 12:00 noon; full proposals close 24 August 2027 at 12:00 noon.
Opening soonCloses Aug 24, 2027May not accept unsolicited proposalsAward: No grant amount specified.
TRT Biology: Radiobiology and Mechanistic Insights in Therapeutic Radiopharmaceuticals
RadiobiologyTherapeutic radiopharmaceuticalsTargeted radionuclide therapy+4 more
Who can apply: Multidisciplinary proposals should link mechanistic biological research on therapeutic radiopharmaceuticals to clinically relevant issues experienced by patients.
Deadline: Pre-proposals open 16 February 2027 and close 13 April 2027 at 12:00 noon; full proposals close 24 August 2027 at 12:00 noon.
Deadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.